• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

INGN 241 in phase II clinical trial

Source: www.biotechnologyhealthcare.com Austin, Texas ? Introgen Therapies announced initiation of a Phase II clinical trial of INGN 241 in patients with metastatic melanoma.

Related Videos
Related Content
SPROUT Trial Highlights Benefits of Apremilast for Pediatric Psoriasis
September 12th 2024

SPROUT Trial Highlights Benefits of Apremilast for Pediatric Psoriasis

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis
August 1st 2023

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis

Availability of Apremilast in US for Pediatric Patients Opens Avenues for Expanded Treatment Options and Oral Therapy
September 9th 2024

Availability of Apremilast in US for Pediatric Patients Opens Avenues for Expanded Treatment Options and Oral Therapy

The Cutaneous Connection
August 5th 2021

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

DPCP Immunotherapy Yields 61.8% Hair Regrowth Rate in Pediatric Alopecia Areata
August 27th 2024

DPCP Immunotherapy Yields 61.8% Hair Regrowth Rate in Pediatric Alopecia Areata

“My Skin My Story” Provides Creative Outlet for Young Patients With Eczema
August 13th 2024

“My Skin My Story” Provides Creative Outlet for Young Patients With Eczema

© 2024 MJH Life Sciences

All rights reserved.